2025 SGBCC Best Poster Awards Announced, Four Chinese Experts Crowned!
On March 13, 2025, the "2025 St. Gallen Breast Cancer Conference (SGBCC) Best Poster Awards" were grandly announced. A total of 482 posters were accepted for this year's SGBCC
EAU 25 | Professors Samson Chan and Junlong Zhuang : PARPi Treatment Shows Initial Efficacy in mHSPC, Advancing Precision Therapy for Prostate Cancer
PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II PROact study conducted by Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University, was reported. The study demonstrated promising preliminary efficacy and safety of the combination of olaparib, abiraterone, and prednisone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). UroStream was honored to invite Prof. Junlong Zhuang from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, and Prof. Samson Chan from Department of Surgery, Tuen Mun Hospital, HONG KONG, to engage in a dialogue and share the latest advancements and clinical experiences in precision therapy for prostate cancer.
Prof. Benlong Yang Named First Chinese Scholar to Receive “Youth Education Ambassador” and “Social Media Ambassador” Titles at SGBCC
The 19th St. Gallen Breast Cancer Conference (SGBCC) took place in Vienna, Austria, from March 12 to 15, 2025. As one of the most prestigious biennial academic events in breast cancer research, SGBCC gathers leading global experts to discuss evolving treatment strategies for early breast cancer, voting on recommendations that shape clinical practice. Notably, this year’s SGBCC will feature a China-focused session, marking a significant milestone. Additionally, Prof. Benlong Yang from Fudan University Shanghai Cancer Center has been named SGBCC’s “Youth Education Ambassador” and “Social Media Ambassador.” This marks the first time a Chinese expert has been awarded such distinctions at SGBCC.
SGBCC Voice of China | Prof. Qiang Liu: Viewing Early Breast Cancer as a Systemic Disease from a ctDNA Perspective
The highly anticipated 19th St. Gallen Breast Cancer Conference (SGBCC) is taking place from March 12 to 15, 2025, in Vienna, Austria. This year, the conference features a special “Voice…
Final TUXEDO-1 Trial Results: Trastuzumab Deruxtecan in HER2+ Breast Cancer with Active Brain Metastases
Published in Neuro-Oncology on July 4, 2024, the final analysis from the phase II TUXEDO-1 trial confirms the strong intracranial and systemic efficacy of trastuzumab deruxtecan (T-DXd) in patients with…
Is Fecal Immunochemical Testing the Right FIT for Patients With Symptoms?
In their recent Gastroenterology editorial, Dr. Audrey H. Calderwood (Dartmouth-Hitchcock Medical Center) and Dr. Theodore R. Levin (Kaiser Permanente) raise a compelling question: can fecal immunochemical testing (FIT) be used beyond colorectal cancer (CRC) screening — to guide colonoscopy decisions in patients with GI symptoms?
Advancing Liver Cancer Treatment: A Cross-Border Dialogue with Dr. Qin Shukui and Dr. Pablo Sarobe
Liver cancer remains one of the deadliest malignancies worldwide, with China carrying a significant burden of cases. Understanding the unique epidemiology, molecular characteristics, and treatment strategies across different regions is crucial for advancing patient outcomes.
In an exclusive cross-border dialogue, Professor Qin Shukui of Nanjing Tianyin Mountain Hospital, China, and Professor Pablo Sarobe of the University of Navarra Medical School, Spain, share their insights into the latest breakthroughs in liver cancer treatment. They discuss the evolving role of immunotherapy, targeted therapy, and the importance of global collaboration in shaping the future of liver cancer care.
Watch the full conversation to gain expert perspectives on emerging treatment strategies, biomarker-driven approaches, and the future of liver cancer therapy.
Dr. Kefeng Ding: Exploration of the Balance between Radical Resection and Functional Preservation in Colorectal Cancer Treatment with LISH Procedure| Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee
At the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Kefeng Ding from The Second Affiliated Hospital Zhejiang University School of Medicine presented innovative advancements in laparoscopic ileocecal-sparing hemicolectomy (LISH) for right-sided colon cancer, highlighting its potential to balance oncologic radicality with functional preservation. His insights provide valuable guidance for clinical practice, promoting precision surgery and organ function preservation in colorectal cancer treatment. Oncology Frontier presents key highlights from his lecture.
Dr. Xiujuan Qu: Breakthroughs in Precision Treatment for Advanced Colorectal Cancer – KRAS G12C Inhibitors Leading the Way
With the discovery of molecular targets and the development of corresponding targeted inhibitors, the treatment of metastatic colorectal cancer (mCRC) is becoming increasingly precise and personalized. At the recent 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee, Dr. Xiujuan Qu from The First Hospital of China Medical University shared the latest advancements in precision treatment for advanced colorectal cancer, including novel therapeutic strategies and the promising role of KRAS G12C inhibitors.
Trastuzumab Deruxtecan in HER2+ Advanced Breast Cancer
New findings from the DESTINY-Breast12 study, published in Nature Medicine on September 13, 2024, highlight the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC), including patients with…
